Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

18
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

540
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
540
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

25
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
25
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

22
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
22
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

645
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
645
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

15.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A dish-to-biobank framework links β-cell nutrient-stress programs to genetic and dietary risk for Type 2 Diabetes.

bioRxiv : the preprint server for biology·2026
Same author

Empirically determined baseline masking strategies and other considerations for gene-level burden tests.

Nature genetics·2026
Same author

Multi-trait polygenic risk scores improve genomic prediction of atrial fibrillation across diverse ancestries.

Nature communications·2026
Same author

Contemporary Perspectives on J-Wave Syndromes: An Expert Consensus Statement.

Journal of arrhythmia·2026
Same author

Atrial Fibrillation and Primary Cilia-Associated Genes: The Role of CEP68.

International journal of molecular sciences·2026
Same author

DNA methylation analysis of NOTCH1 variants reveals the first episignature for non-syndromic congenital heart defects.

Genome medicine·2026

Related Experiment Video

Updated: Feb 20, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First

Guilherme L da Rocha1, James Feiner2, Julieta Lazarte3

  • 1Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada.

Journal of the American College of Cardiology
|February 18, 2026
PubMed
Summary

Genetic variants causing cardiomyopathy increase atrial fibrillation (AF) risk, even without heart failure. Combining genetic risk scores with these variants helps predict atrial versus ventricular disease development.

Keywords:
atrial fibrillationcardiomyopathygenetics

More Related Videos

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.8K
Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

2.2K

Related Experiment Videos

Last Updated: Feb 20, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.8K
Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

2.2K

Area of Science:

  • Cardiovascular Genetics
  • Genomics
  • Medical Genetics

Background:

  • Atrial fibrillation (AF) is a heritable condition with a complex genetic basis.
  • Understanding the genetic links between AF and cardiomyopathies is crucial for risk stratification.

Purpose of the Study:

  • To investigate the impact of cardiomyopathy-causing variants on AF risk.
  • To assess the utility of polygenic risk scores (PRS) in differentiating atrial and ventricular disease risks.

Main Methods:

  • Cox regression analysis was used to assess associations between cardiomyopathy variants and AF.
  • Disease-specific PRSs for AF, dilated cardiomyopathy (DCM), and hypertrophic cardiomyopathy (HCM) were utilized.
  • Meta-analysis and Kaplan-Meier methods were employed to evaluate cumulative incidence.

Main Results:

  • Disease-causing variants were associated with a 1.73-fold increased hazard of AF (P < 0.001).
  • This association persisted after adjusting for ventricular cardiomyopathy or heart failure (adjusted HR: 1.55).
  • Individuals with high-risk variants and PRS showed significantly higher cumulative AF and cardiomyopathy risks.

Conclusions:

  • Cardiomyopathy-associated genetic variants elevate AF risk, independent of overt ventricular disease or heart failure.
  • Integrating disease-specific PRSs with these variants aids in predicting the likelihood of developing atrial or ventricular disease.
  • Genes causing cardiomyopathy may have a substantial, often equal or greater, impact on AF risk.